🇺🇸 FDA
Patent

US 12161733

Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer

granted A61KA61K31/4025A61K45/06

Quick answer

US patent 12161733 (Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/4025, A61K45/06, A61K47/547, A61K49/0052